Myeloproliferative neoplasm laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myeloproliferative disease}}
{{Myeloproliferative disease}}
{{CMG}} {{AE}} {{MJK}}
{{CMG}} {{AE}} {{MJK}} {{shyam}}
==Overview==
==Overview==
Laboratory findings consistent with the diagnosis of myeloproliferative neoplasm include [[leukocytosis]], [[thrombocytopenia]], and [[anemia]].
Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include [[leukocytosis]], [[thrombocytopenia]], and [[anemia]].
==Laboratory Findings==
==Laboratory Findings==
Laboratory findings associated with myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{Cite journal
Laboratory findings associated with myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{Cite journal
Line 16: Line 16:
  | doi = 10.1309/AJCPUN89CXERVOVH
  | doi = 10.1309/AJCPUN89CXERVOVH
  | pmid = 19605820
  | pmid = 19605820
}}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref><ref name="O'Brien2004">{{cite journal|last1=O'Brien|first1=S.|title=Chronic Myelogenous Leukemia and Myeloproliferative Disease|journal=Hematology|volume=2004|issue=1|year=2004|pages=146–162|issn=1520-4391|doi=10.1182/asheducation-2004.1.146}}</ref>
}}</ref><ref name="Sánchez-MuñozAlvarez-Twose2011">{{cite journal|last1=Sánchez-Muñoz|first1=Laura|last2=Alvarez-Twose|first2=Ivan|last3=García-Montero|first3=Andrés C|last4=Teodosio|first4=Cristina|last5=Jara-Acevedo|first5=María|last6=Pedreira|first6=Carlos E|last7=Matito|first7=Almudena|last8=Morgado|first8=Jose Mario T|last9=Sánchez|first9=Maria Luz|last10=Mollejo|first10=Manuela|last11=Gonzalez-de-Olano|first11=David|last12=Orfao|first12=Alberto|last13=Escribano|first13=Luis|title=Evaluation of the WHO criteria for the classification of patients with mastocytosis|journal=Modern Pathology|volume=24|issue=9|year=2011|pages=1157–1168|issn=0893-3952|doi=10.1038/modpathol.2011.84}}</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref><ref name="O'Brien2004">{{cite journal|last1=O'Brien|first1=S.|title=Chronic Myelogenous Leukemia and Myeloproliferative Disease|journal=Hematology|volume=2004|issue=1|year=2004|pages=146–162|issn=1520-4391|doi=10.1182/asheducation-2004.1.146}}</ref><ref name="pmid23606974">{{cite journal| author=Murakami J, Shimizu Y| title=Hepatic manifestations in hematological disorders. | journal=Int J Hepatol | year= 2013 | volume= 2013 | issue=  | pages= 484903 | pmid=23606974 | doi=10.1155/2013/484903 | pmc=PMC3626309 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23606974  }} </ref>
*[[Complete blood count]]
*[[Complete blood count]]
:*Increased [[granulocyte]]s of all types
:*Increased [[granulocyte]]s of all types
:*Increased [[basophil]]s and [[eosinophil]]s
:*Increased [[basophil]]s and [[eosinophil]]s
:*[[Thrombocytopenia]]
:*[[Thrombocytopenia]] or thrombocythemia
:*[[Anemia]]
:*[[Anemia]] or [[polycythemia]]
:*Red blood cell mass test
*Blood chemistry
*Blood chemistry
:*The following blood levels may be elevated:
:*The following blood levels may be elevated:
Line 32: Line 31:
::*[[Aspartate transaminase]] (AST)
::*[[Aspartate transaminase]] (AST)
::*[[Uric acid]]
::*[[Uric acid]]
*Bleeding and clotting factor
*Bleeding and clotting factors
:*The following blood levels may be elevated:
:*The following blood parameters may be elevated:
::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR)
::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR)
::*[[Partial thromboplastin time]] (PTT)
::*[[Partial thromboplastin time]] (PTT)
*[[Cytochemistry]]
::*[[D-dimer]]
:*Cytochemistry helps determine the type of cells that are present
*[[Flow cytometry]]
*[[Flow cytometry]]
:* Flow cytometry helps determine the type of cells that are present
:* Flow cytometry helps determine the type of cells that are present.
*[[Cytogenetics]]
*[[Cytogenetics]] or [[karyotyping]]
:*Chromosome changes that may occur in some people with leukemia include:
:*Chromosome changes that may occur in some people with leukemia include:
::*[[Translocations]]
::*[[Translocations]]
::*Inversions
::*[[Inversions]]
::*loss or gain of a chromosome number
::*Loss or gain of a chromosome
*[[Fluorescent in situ hybridization]] (FISH)
*[[Fluorescent in situ hybridization]] (FISH)
:*Similar to cytogenetics, but more specific
:*Similar to cytogenetics, but more specific for particular chromosomal translocations
*Polymerase chain reaction
*Polymerase chain reaction
:*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
:*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
* Neutrophil alkaline phosphatase level
*Neutrophil alkaline phosphatase level
* [[Vitamin B12]] (or B12 binding capacity)
*[[Vitamin B12]] (or B12 binding capacity) level
*Erythropoietin level
*Molecular testing for ''JAK2'', ''CALR'', and ''MPL'' mutations


==Gallery==
==Gallery==
Line 66: Line 66:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]

Latest revision as of 21:48, 21 June 2018

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm laboratory findings

on Myeloproliferative neoplasm laboratory findings

Myeloproliferative neoplasm laboratory findings in the news

Blogs on Myeloproliferative neoplasm laboratory findings

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.

Laboratory Findings

Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]

  • Blood chemistry
  • The following blood levels may be elevated:
  • Bleeding and clotting factors
  • The following blood parameters may be elevated:
  • Flow cytometry helps determine the type of cells that are present.
  • Chromosome changes that may occur in some people with leukemia include:
  • Similar to cytogenetics, but more specific for particular chromosomal translocations
  • Polymerase chain reaction
  • Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
  • Neutrophil alkaline phosphatase level
  • Vitamin B12 (or B12 binding capacity) level
  • Erythropoietin level
  • Molecular testing for JAK2, CALR, and MPL mutations

Gallery

References

  1. Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
  2. James W. Vardiman (2009). "Chronic myelogenous leukemia, BCR-ABL1+". American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter |month= ignored (help)
  3. Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). "Evaluation of the WHO criteria for the classification of patients with mastocytosis". Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
  4. Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
  5. O'Brien, S. (2004). "Chronic Myelogenous Leukemia and Myeloproliferative Disease". Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
  6. Murakami J, Shimizu Y (2013). "Hepatic manifestations in hematological disorders". Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
  7. Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review". Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.

Template:WH Template:WS